Why Integer (ITGR) is a Top Momentum Stock for the Long-Term

Integer Holdings Corporation (ITGR), a medical device contract development and manufacturing organization, is highlighted as a top momentum stock, holding a Zacks #2 (Buy) Rank and a 'B' Momentum Style Score. This positive assessment is reinforced by a recent upward revision in its fiscal 2025 earnings estimate, pushing the Zacks Consensus Estimate to $6.33 per share, indicating strong analyst sentiment and potential investment appeal.

Analysis

Integer Holdings Corporation (ITGR) is presented with a favorable outlook based on the Zacks rating methodology, holding a #2 (Buy) rank. This bullish stance is underpinned by positive signals in its earnings profile and momentum characteristics, meriting a 'B' for both its Momentum and overall VGM Style Scores. A key driver is an upward revision in analyst sentiment for fiscal 2025, where the consensus earnings estimate was recently increased by $0.07 to $6.33 per share following a revision by one analyst in the past 60 days. This forward-looking optimism is supported by the company's historical performance, which includes a consistent average earnings surprise of 2.8%. Despite the positive fundamental and earnings momentum indicators, the stock's recent price momentum has been muted, with shares gaining only 0.1% over the past four weeks, suggesting the positive sentiment has not yet fully translated into significant price appreciation.

Key Decisions for Investors

• Given the #2 (Buy) rating and the upward revision in the fiscal 2025 consensus EPS to $6.33, investors may view ITGR as a fundamentally strong candidate, especially if their strategy prioritizes positive earnings estimate revisions.
• Momentum-focused investors should note the contrast between the stock's 'B' Momentum score, based on earnings trends, and its recent flat price performance of +0.1%, indicating a potential opportunity if a catalyst triggers price appreciation to align with the positive earnings outlook.
• Considering the analysis relies heavily on the proprietary Zacks framework and a single analyst revision, it is prudent to corroborate this view with additional due diligence on industry trends and the company's upcoming financial reports before initiating or adding to a position.